Fosun Kairos

Fuxing Kerry (Shanghai) Biological Technology, founded in 2017, is a high-tech biopharmaceutical company under Fuxing Pharmaceuticals, specializing in tumor cell therapy product development, industrialization, and commercialization.

ElpasBio partners with Fosun Kairos to commercialize its **AlloJoin® (lotazadromcel)**, an allogeneic human adipose-derived mesenchymal stem cell therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR. The investigational therapy, derived from adipose tissue, targets regenerative treatment of KOA. This collaboration expands market access for ElpasBio’s clinical-stage regenerative medicine pipeline.

Jan 2026Yahoo FinanceNews article

Fosun Kairos raises up to **RMB 600 million** in Series A funding from the Shenzhen Biopharmaceutical Industry Fund. The investment supports cell-therapy research and expansion, with proceeds allocated to operations and development of Fosun Kairos and its subsidiaries. The fund subscribes for **RMB 524.4 million** in new registered capital.

Oct 2025Insight, China's Pharmaceutical IndustryNews article

Axi-Cel, branded as **Yikaida** in China, receives approval for **second-line treatment** of patients with **refractory or relapsed large B-cell lymphoma (LBCL)**. The therapy, developed by **Kite, a Gilead company**, expands its clinical use in China beyond first-line indications. Regulatory clearance follows prior success in treating relapsed or refractory LBCL in other markets.

Sep 2023cgtlive.comNews article

Fosun Kite secures regulatory approval in China for its CAR T-cell therapy, **Yikaida (Yescarta in other markets)**, expanding its use to treat **large B-cell lymphoma patients** who have progressed after one prior treatment. The therapy joins Fosun Kite’s growing portfolio of immunotherapies for blood cancers. China’s approval follows earlier market authorizations in the U.S. and Europe.

Jul 2023genomeweb.comNews article